We first determined the cellular mechanisms for this improvement in bone structure with anti‐LRP6, and whether this LRP6‐targeted agent prevents the development of osteolytic bone loss utilizing the 5TGM1 murine model of MM. The gene discussed is LRP6; the disease is Miyoshi myopathy.